SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
43.96
+0.26 (+0.59%)
At close: 4:02PM EST

43.92 -0.03 (-0.07%)
Pre-Market: 8:30AM EST

Stock chart is not supported by your current browser
Previous Close43.70
Open43.85
Bid43.99 x 1100
Ask44.02 x 1500
Day's Range43.82 - 44.05
52 Week Range38.45 - 50.65
Volume835,238
Avg. Volume1,231,765
Market Cap109.827B
Beta0.78
PE Ratio (TTM)10.47
EPS (TTM)4.20
Earnings DateN/A
Forward Dividend & Yield1.64 (3.79%)
Ex-Dividend Date2017-05-11
1y Target Est49.50
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    Sanofi CEO says M&A targets in oncology are 'very expensive'

    PARIS (Reuters) - Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very expensive". "If you are not starting with ...

  • Reuters3 hours ago

    France's Sanofi pins hopes on new drugs after setbacks

    French pharmaceuticals group Sanofi said on Wednesday it had suffered from low uptake for a new cholesterol drug and from concerns about a dengue vaccine, but expressed confidence its pipeline of new products would support long-term growth. The world's sixth largest drugmaker, which is battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine regulatory submissions in the next 18 months. Shares in Sanofi were down 0.54 percent at 1100 GMT.

  • Reuters3 hours ago

    France's Sanofi pins hopes on new drugs after setbacks

    French pharmaceuticals group Sanofi said on Wednesday it had suffered from low uptake for a new cholesterol drug and from concerns about a dengue vaccine, but expressed confidence its pipeline of new products would support long-term growth. The world's sixth largest drugmaker, which is battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine regulatory submissions in the next 18 months. Shares in Sanofi were down 0.54 percent at 1100 GMT.

  • GlobeNewswire8 hours ago

    Sanofi : Sanofi presents R&D strategy and innovative pipeline

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   Sanofi presents R&D strategy and innovative pipeline                   ·         Robust pipeline expected to support long-term growth                   ·         ...

  • GlobeNewswire8 hours ago

    Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

    Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma High and ...

  • Reuters8 hours ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • Reuters12 hours ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON, Dec 12 (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • CNW Group20 hours ago

    The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

    The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

  • TheStreet.com23 hours ago

    Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi

    French drug-maker Sanofi contends its Dengue vaccine is good for the country. After 730,000 children were vaccinated, the Philippine government stopped the program on data the drug-maker released that ...

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacks23 hours ago

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • Reutersyesterday

    Sanofi investors hungry for drug progress and deal news

    Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reutersyesterday

    Sanofi investors hungry for drug progress and deal news

    Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • PR Newswire2 days ago

    FDA Approves Sanofi's Admelog® (insulin lispro injection)

    PARIS, Dec. 11, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sanofi's Admelog®, the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime. "Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes.

  • Reuters2 days ago

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reuters2 days ago

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • GlobeNewswire2 days ago

    FDA Approves Sanofi's Admelog® (insulin lispro injection)

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA Approves Sanofi`s Admelog ® (insulin lispro injection) First FDA-approved follow-on mealtime insulin Admelog (insulin lispro injection) 100 ...

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool2 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
    Zacks2 days ago

    Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Sanofi Begins Combo Studies on Multiple Myeloma Candidate
    Zacks5 days ago

    Sanofi Begins Combo Studies on Multiple Myeloma Candidate

    Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

  • Market Realist5 days ago

    How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing

    In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.

  • Philippines wants money back from Sanofi for dengue vaccine
    Associated Press5 days ago

    Philippines wants money back from Sanofi for dengue vaccine

    MANILA, Philippines (AP) — The Philippine government will demand a refund of 3.5 billion pesos ($69.5 million) from vaccine maker Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness, the health chief said Friday.

  • Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
    Zacks5 days ago

    Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

    FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

  • Reuters5 days ago

    Philippines to seek refund of $59 million from Sanofi amid vaccine risk

    The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunise hundreds of thousands of children that Sanofi has said could worsen the disease in some cases. "We will demand the refund of the 3 billion (pesos) paid for the Dengvaxia and (demand) that Sanofi set up an indemnification fund to cover the hospitalisation and medical treatment of all children who might have severe dengue," Health Secretary Francisco Duque told reporters on Friday. The Philippines last week suspended a national immunisation programme after Sanofi's recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia.

  • Business Wire6 days ago

    Sanofi explores combination treatments for multiple myeloma in new late-stage trials

    Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia.

  • Sanofi's Pointeau on China Strategy, Partnerships
    Bloomberg Video6 days ago

    Sanofi's Pointeau on China Strategy, Partnerships

    Dec.07 -- Jean-Christophe Pointeau, China country chair at Sanofi, discusses the changes in the Chinese health market, his business strategy in China, his partnerships and the automation of the industry. He speaks on "Bloomberg Markets: Asia" from the Fortune Global Forum in Guangzhou.